Overall impact
B (78)

Commentary

Biostage is a strong overall performer. With a 'B' rating of 78.0 for overall impact (92nd percentile compared to all companies), Biostage ranks 8th out of 103 industry peers, behind Endologix, RA Medical Systems, Sonova and 4 others, and ahead of Waters, MyMD Pharmaceuticals, Alphatec and 92 others. On top material causes for Biostage's industry (Healthcare Equipment), Biostage performs well in Child and Maternal Health (93.2 score), Child and Maternal Health (95.0), Disease Eradication (95.7) and 5 other causes where it received an 'A' score and performs poorly in Accountable Institutions (33.4 score).
Impact
Cause BSTG
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2009
Employees
7
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ma, United States
Share classes
BSTG
Description
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Material causes
Ethos considers the following causes material for Biostage, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.